Serina Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $27.04M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | After market close | – | $-0.55 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 25, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | Before market open | – | $-0.45 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | After market close | $130.00K | $-0.66 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 24, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | $14.00K | $0.13 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 9, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 22, 2024 | After market close | – | – | – |
Press releases
Announcements Serina Therapeutics filed with the SEC
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s Disease
Material agreement · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson’s disease
Other events · EX-99.1 to Form 8-K
Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program
Other events · EX-99.1 to Form 8-K
Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
Results of operations · EX-99.1 to Form 8-K
Serina Therapeutics Provides Regulatory Update on SER-252 Program
Other events · EX-99.1 to Form 8-K
Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson’s Disease
Other events · EX-99.1 to Form 8-K
Serina Therapeutics Secures Up to $20 Million to Advance
Regulation FD disclosure · EX-99.1 to Form 8-K
Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
Results of operations · EX-99.1 to Form 8-K
Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)
Regulation FD disclosure · EX-99.2 to Form 8-K
Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors
Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
Results of operations · EX-99.1 to Form 8-K
Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit
Regulation FD disclosure · EX-99 to Form 8-K
Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference
Regulation FD disclosure · EX-99.2 to Form 8-K
Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting
Regulation FD disclosure · EX-99.1 to Form 8-K
HIGHLY CONFIDENTIAL & TRADE SECRET 1 March 2025 ACS – Division of Polymer Chemistry Characterization of Poly(oxazoline) Lipid Nanoparticles (LNP) A Non-immunogenic LNP for Gene Delivery Randall Moreadith, MD, PhD, Chief Development Officer [email protected]
Regulation FD disclosure · EX-99.2 to Form 8-K
Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients
Regulation FD disclosure · EX-99.1 to Form 8-K
New / improved small molecule drugs POZ Platform® December 2024 Non confidential Small Molecules Enabling Improvements of Multiple Drug Modalities Optimized targeting & reduced immunogenicity RNA Improved delivery of cancer-killing toxins ADCs
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit
Regulation FD disclosure · EX-99.2 to Form 8-K
Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics to Present at the 14th Annual Injectables Summit
Regulation FD disclosure · EX-99.2 to Form 8-K
Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the
Regulation FD disclosure · EX-99.2 to Form 8-K